Business Context and Reporting Period
This Form 8-K was filed by Millendo Therapeutics, Inc. (trading symbol: MLND) on February 10, 2020. The report covers events occurring on that date, specifically executive leadership changes and clinical trial updates. Note: The request metadata references "Tempest Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Millendo Therapeutics, Inc.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding specific corporate events and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Executive Appointment: Christophe Arbet-Engels, MD, PhD, joined the Company as Chief Medical Officer.
- Clinical Trial Update: The Company anticipates receiving topline results from the Phase 2b portion of its Phase 2b/3 clinical trial for livoletide in Prader-Willi syndrome patients early in the second quarter of 2020.
Guidance, Outlook, and Risks
Management provided a timeline for upcoming clinical data, expecting topline results for livoletide in Q2 2020. The filing does not contain specific financial guidance, risk factor updates, or disclosures of contingencies beyond the standard incorporation of the press release.
Investor Verification Checklist
- Verify the identity of the registrant (Millendo Therapeutics, Inc.) versus the metadata request (Tempest Therapeutics, Inc.).
- Review the attached press release (Exhibit 99.1) for detailed information on the new Chief Medical Officer's background.
- Monitor the Company's announcements in Q2 2020 for the release of livoletide Phase 2b topline results.
- Consult the most recent 10-K or 10-Q filings for current financial position and liquidity metrics, as they are absent in this 8-K.